CA3090063A1 - Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use - Google Patents

Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use Download PDF

Info

Publication number
CA3090063A1
CA3090063A1 CA3090063A CA3090063A CA3090063A1 CA 3090063 A1 CA3090063 A1 CA 3090063A1 CA 3090063 A CA3090063 A CA 3090063A CA 3090063 A CA3090063 A CA 3090063A CA 3090063 A1 CA3090063 A1 CA 3090063A1
Authority
CA
Canada
Prior art keywords
compound
certain embodiments
hydrogen
methyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3090063A
Other languages
English (en)
French (fr)
Inventor
Irit SNIR-ALKALAY
Joseph Vacca
Yinon Ben-Neriah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of CA3090063A1 publication Critical patent/CA3090063A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3090063A 2018-02-08 2019-02-07 Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use Pending CA3090063A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862627921P 2018-02-08 2018-02-08
US201862627908P 2018-02-08 2018-02-08
US62/627,921 2018-02-08
US62/627,908 2018-02-08
PCT/IL2019/050151 WO2019155468A1 (en) 2018-02-08 2019-02-07 Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use

Publications (1)

Publication Number Publication Date
CA3090063A1 true CA3090063A1 (en) 2019-08-15

Family

ID=65635772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3090063A Pending CA3090063A1 (en) 2018-02-08 2019-02-07 Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use

Country Status (11)

Country Link
US (2) US20200383984A1 (enExample)
EP (1) EP3749666A1 (enExample)
JP (1) JP2021512922A (enExample)
KR (1) KR20200130287A (enExample)
CN (1) CN111971280A (enExample)
AU (1) AU2019219678A1 (enExample)
BR (1) BR112020016064A2 (enExample)
CA (1) CA3090063A1 (enExample)
IL (1) IL276290A (enExample)
MX (1) MX2020008375A (enExample)
WO (1) WO2019155468A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62728B1 (sr) 2015-08-04 2022-01-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivat pirazol pirimidina i njegove upotrebe
EP3976600B1 (en) * 2019-06-03 2026-05-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Non-hygroscopic crystalline salts of a pyrazole compound, pharmaceutical compositions containing them and their use
AU2021209057A1 (en) * 2020-01-13 2022-06-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pyrazolylpyrimidines and use thereof
US20240207268A1 (en) * 2021-03-24 2024-06-27 Biotheryx, Inc. Pyrazolylpyrimidines for treating malignant solid tumor
US11752151B2 (en) * 2021-07-12 2023-09-12 Buddhist Tzu Chi Medical Foundation Method for enhancing hair growth
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
WO2023232245A1 (en) * 2022-06-01 2023-12-07 Symrise Ag Fragrances with cyclopropyl structure

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637809A (en) 1968-07-05 1972-01-25 Ciba Geigy Corp Antioxidants
US3698123A (en) 1971-12-06 1972-10-17 Carl R Heldt Structural toys
US3917899A (en) 1972-08-04 1975-11-04 Michael J Oliver Plate for adjustably mounting electrical receptacle
US3846770A (en) 1973-07-11 1974-11-05 Us Navy Serial access memory using magnetic domains in thin film strips
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2839461C2 (de) 1978-09-11 1987-01-15 Bergwerksverband Gmbh, 4300 Essen Formmassen aus thermoplastischen Kunststoffen und Rückständen der Kohlehydrierung
US4328246A (en) 1979-08-14 1982-05-04 Joseph Gold Anti Walker 256 carcinoma agent and combination thereof
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US5762756A (en) 1994-11-21 1998-06-09 The Black Clawson Company Methods and apparatus for pulping and deinking
US6069696A (en) 1995-06-08 2000-05-30 Psc Scanning, Inc. Object recognition system and method
US6576139B1 (en) 1996-07-30 2003-06-10 Kenneth C. Hou Process for purifying photoresist composition employing a filter sheet
DE19630939C1 (de) 1996-07-31 1997-12-11 Siemens Ag Kontaktfeder
KR100218318B1 (ko) 1996-10-01 1999-09-01 문정환 주파수 변환장치
US7274662B1 (en) 1998-08-04 2007-09-25 At&T Corp. Method for performing segmented resource reservation
US6062668A (en) 1996-12-12 2000-05-16 Hitachi Koki Imaging Solutions, Inc. Drop detector for ink jet apparatus
US6364667B1 (en) 1997-03-14 2002-04-02 Relational Technologies Llp Techniques for mastering a body of knowledge by writing questions about the body of knowledge
US6073643A (en) 1998-09-14 2000-06-13 Patent Category Corp. Adjustable collapsible panels
DE60039616D1 (de) * 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
DE20019821U1 (de) 1999-12-09 2001-06-07 BRAND GMBH + CO KG, 97877 Wertheim Dosiereinrichtung für Flüssigkeiten
EP1188148A2 (en) 2000-01-27 2002-03-20 Koninklijke Philips Electronics N.V. Method and system for extracting spine geometrical data
US6691777B2 (en) 2000-08-15 2004-02-17 Baker Hughes Incorporated Self-lubricating swage
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US6947491B2 (en) 2000-09-13 2005-09-20 Interdigital Technology Corporation Third generation FDD modem interleaver
AU2001296496A1 (en) 2000-10-02 2002-04-15 The University Of Akron Synthesis and characterization of nanocomposites by emulsion polymerization
US7113943B2 (en) 2000-12-06 2006-09-26 Content Analyst Company, Llc Method for document comparison and selection
US7120761B2 (en) 2000-12-20 2006-10-10 Fujitsu Limited Multi-port memory based on DRAM core
JP4007767B2 (ja) 2001-01-18 2007-11-14 日本碍子株式会社 圧電／電歪デバイスおよびその製造方法
US6709874B2 (en) 2001-01-24 2004-03-23 Infineon Technologies Ag Method of manufacturing a metal cap layer for preventing damascene conductive lines from oxidation
US6980946B2 (en) 2001-03-15 2005-12-27 Microsoft Corporation Method for hybrid processing of software instructions of an emulated computer system
WO2002077657A1 (en) 2001-03-22 2002-10-03 Fujitsu Limited Magnetoresistive spin-valve sensor and magnetic storage apparatus
JP4124607B2 (ja) 2001-04-06 2008-07-23 ヤマウチ株式会社 ピンチローラおよびピンチローラ装置
US6840774B2 (en) 2001-05-07 2005-01-11 Jack W. Fretwell, Jr. System to teach, measure and rate learner knowledge of basic mathematics facts
US6798220B1 (en) 2001-06-27 2004-09-28 Timothy H. Flanigan Moisture/mold detector
CA2452603A1 (en) * 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
US6891474B1 (en) 2001-08-01 2005-05-10 Tagsense, Inc. Electromagnetic identification label for anti-counterfeiting, authentication, and tamper-protection
US7345559B2 (en) 2001-09-13 2008-03-18 General Electric Company High field open MRI magnet isolation system and method
US6965468B2 (en) 2003-07-03 2005-11-15 Reflectivity, Inc Micromirror array having reduced gap between adjacent micromirrors of the micromirror array
US7039976B2 (en) 2002-04-09 2006-05-09 Maytag Corporation Braking control system for a washing machine
US6739477B1 (en) 2002-04-12 2004-05-25 Floro Pascual Golf ball dispenser
US7048737B2 (en) 2002-06-11 2006-05-23 Bioplate, Inc. Cranial bone flap fixation system and method
WO2004001741A1 (en) 2002-06-21 2003-12-31 Seagate Technology Llc Fluid dynamic bearing asymmetry pressure feedback
CA2496197A1 (en) * 2002-08-20 2004-03-04 Neurogen Corporation 5-substituted-2-arylpyrazines as modulators of crf receptors
DE10240053A1 (de) 2002-08-30 2004-03-11 Robert Bosch Gmbh Brückenzünder-Zündelement
US6739108B2 (en) 2002-09-30 2004-05-25 Allpax Products, Inc. Fragile container handling system for retort/sterilization processes
JP2004158619A (ja) 2002-11-06 2004-06-03 Matsushita Electric Ind Co Ltd 電子デバイスおよびその製造方法
US6712069B1 (en) 2002-11-20 2004-03-30 William L. Spangler Solar energy collection and storage system
US7139876B2 (en) 2003-01-16 2006-11-21 Ip-First, Llc Microprocessor and apparatus for performing fast speculative pop operation from a stack memory cache
ITBO20030105A1 (it) 2003-02-28 2004-09-01 Fasco Spa Pistola pneumatica per elementi di fissaggio.
US7360468B2 (en) 2003-03-19 2008-04-22 Nsk Ltd. Electric power steering device and resin gear used for the same
US7248373B2 (en) 2003-03-21 2007-07-24 Durr Systems, Inc Workpiece configuration detection system and method
US6867376B2 (en) 2003-04-17 2005-03-15 Bellsouth Intellectual Property Corporation Glow rods with externally mountable anchoring members and related methods
US7069377B2 (en) 2003-05-08 2006-06-27 Micron Technology, Inc. Scratch control memory array in a flash memory device
FR2854693B1 (fr) 2003-05-09 2005-07-01 Siemens Vdo Automotive Procede de determination de l'energie d'un signal de cliquetis pour moteur a combustion interne
WO2004112800A1 (en) 2003-06-19 2004-12-29 Bodor Nicholas S Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
US6993866B1 (en) 2003-06-25 2006-02-07 James Strange Fishing bait rig attachment apparatus with rotating rattle
US6922367B2 (en) 2003-07-09 2005-07-26 Micron Technology, Inc. Data strobe synchronization circuit and method for double data rate, multi-bit writes
JP4183181B2 (ja) 2003-08-07 2008-11-19 株式会社小松製作所 異物除去装置
DE102004027446B4 (de) 2004-06-04 2007-08-23 Jungheinrich Aktiengesellschaft Vorrichtung zur Unterstützung des Ein- und Ausstapelns bei einem Stapler
US7197360B1 (en) 2005-01-12 2007-03-27 Pacesetter, Inc. Methods and systems for using an inductor to increase capacitor reformation efficiency in an implantable cardiac device (ICD)
US7377471B1 (en) 2005-06-06 2008-05-27 Compton Harry L Method and system for opening and securing a railroad frog
US7271369B2 (en) 2005-08-26 2007-09-18 Aem, Inc. Multilayer positive temperature coefficient device and method of making the same
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
JP4666514B2 (ja) 2006-07-20 2011-04-06 リンテック株式会社 シート剥離装置及び剥離方法
US7799600B2 (en) 2007-05-31 2010-09-21 Chien-Min Sung Doped diamond LED devices and associated methods
US7689648B2 (en) 2007-06-27 2010-03-30 Microsoft Corporation Dynamic peer network extension bridge
WO2010145208A1 (en) * 2009-06-19 2010-12-23 Abbott Laboratories Diazahomoadamantane derivatives and methods of use thereof
US9458156B2 (en) * 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10179125B2 (en) * 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CN107406438B (zh) * 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
JP2016193861A (ja) * 2015-03-31 2016-11-17 国立大学法人山梨大学 マスト細胞活性化を抑制するための医薬組成物
RS62728B1 (sr) * 2015-08-04 2022-01-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivat pirazol pirimidina i njegove upotrebe
WO2017021970A1 (en) 2015-08-06 2017-02-09 Tower-Sec Ltd Means and methods for regulating can communication
EP3362451B1 (en) * 2015-12-09 2023-04-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
JP6799752B2 (ja) * 2016-10-13 2020-12-16 パナソニックＩｐマネジメント株式会社 光ディスク装置、光ディスク読み出し方法
WO2018142393A1 (en) * 2017-02-01 2018-08-09 Yissum Research Development Company Of The Hebrew N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer

Also Published As

Publication number Publication date
IL276290A (en) 2020-09-30
US20230233562A1 (en) 2023-07-27
CN111971280A (zh) 2020-11-20
KR20200130287A (ko) 2020-11-18
AU2019219678A1 (en) 2020-08-27
BR112020016064A2 (pt) 2020-12-08
US20200383984A1 (en) 2020-12-10
WO2019155468A1 (en) 2019-08-15
JP2021512922A (ja) 2021-05-20
US12138265B2 (en) 2024-11-12
EP3749666A1 (en) 2020-12-16
MX2020008375A (es) 2020-09-25

Similar Documents

Publication Publication Date Title
US12138265B2 (en) Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
CA2943220C (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US20240025863A1 (en) Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
EP4355741B1 (en) Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
ES2474615T3 (es) Antagonistas de CCR3 arilsulfonamidas 2,5-disustituidas
US20240190883A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2024012557A1 (en) Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
CA3146157A1 (en) Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
CA3146159A1 (en) Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
CA3024118A1 (en) Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
KR20240027583A (ko) 폐암 치료를 위한 피리미디닐아미노벤젠
WO2025038987A2 (en) Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications
US12570687B2 (en) Triterpenoid compounds, pharmaceutical compositions thereof, and their use for treating a nuclear receptor subfamily 4 group a member 1-mediated disease
ES2805528T3 (es) Inhibidores de 3,5-diaminopirazol quinasa
JP2025514839A (ja) Ｃｄｋ阻害剤、医薬組成物及びその治療応用
JP2025541836A (ja) ホスホロアミダートモノサッカライド、医薬組成物、並びに診断的及び治療的応用
WO2024120466A1 (en) Monosaccarides, pharmaceutical compositions, and diagnostic and therapeutic applications
HK40056179A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211223